Survodutide 6mg

Survodutide is a dual glucagon receptor/GLP-1 receptor agonist developed by Boehringer Ingelheim. Unlike pure GLP-1 agonists (semaglutide) or GIP/GLP-1 dual agonists (tirzepatide), survodutide combines GLP-1 receptor agonism with glucagon receptor agonism. This represents a distinct pharmacological approach based on the understanding that glucagon, despite its role in raising blood glucose, has significant beneficial metabolic effects when combined with GLP-1 activity. Glucagon receptor activation increases hepatic energy expenditure through enhanced lipid oxidation, promotes thermogenesis, and can reduce hepatic lipid accumulation — effects that are particularly relevant for non-alcoholic steatohepatitis (NASH/MASH). However, glucagon's hyperglycemic effect limits its standalone therapeutic use. By combining glucagon activity with GLP-1-mediated insulin stimulation and glucose control, survodutide aims to capture glucagon's metabolic benefits while offsetting its glucose-raising properties. Phase II clinical trials have shown particularly promising results in liver fat reduction. The GCKR-mediated increase in hepatic fatty acid oxidation driven by glucagon, combined with GLP-1-mediated appetite suppression and improved insulin sensitivity, creates a metabolic profile well-suited to NASH/MASH treatment. Survodutide has demonstrated superior liver fat reduction compared to pure GLP-1 agonists in head-to-head analyses.

Survodutide is a dual glucagon receptor/GLP-1 receptor agonist developed by Boehringer Ingelheim. Unlike pure GLP-1 agonists (semaglutide) or GIP/GLP-1 dual agonists (tirzepatide), survodutide combines GLP-1 receptor agonism with glucagon receptor agonism. This represents a distinct pharmacological approach based on the understanding that glucagon, despite its role in raising blood glucose, has significant beneficial metabolic effects when combined with GLP-1 activity. Glucagon receptor activation increases hepatic energy expenditure through enhanced lipid oxidation, promotes thermogenesis, and can reduce hepatic lipid accumulation — effects that are particularly relevant for non-alcoholic steatohepatitis (NASH/MASH). However, glucagon's hyperglycemic effect limits its standalone therapeutic use. By combining glucagon activity with GLP-1-mediated insulin stimulation and glucose control, survodutide aims to capture glucagon's metabolic benefits while offsetting its glucose-raising properties. Phase II clinical trials have shown particularly promising results in liver fat reduction. The GCKR-mediated increase in hepatic fatty acid oxidation driven by glucagon, combined with GLP-1-mediated appetite suppression and improved insulin sensitivity, creates a metabolic profile well-suited to NASH/MASH treatment. Survodutide has demonstrated superior liver fat reduction compared to pure GLP-1 agonists in head-to-head analyses.

Phase II clinical trials studied subcutaneous doses of 0.6 mg to 4.8 mg weekly with dose escalation protocols. The 6mg vial provides research-grade material for in vitro and preclinical studies.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.